In a bid to expand its oncology portfolio, Jazz Pharmaceuticals has agreed to license the US rights todevelop and commercialise lurbinectedin from PharmaMar in a deal worth up to US$1 B. Lurbinectedin is a selective inhibitor of the oncogenic transcription programmes on which many tumours are particularly dependent. PharmaMar submitted a NDA to the FDA in December 2019 for the accelerated approval of lurbinectedin as Zepsyre® for the treatment of relapsed small cell lung cancer with the potential to launch the drug in 2020.